Literature DB >> 11770297

Novel chemotherapeutic approaches to brain tumors.

E J Dropcho1.   

Abstract

In reviewing the numerous investigational drug trials for patients with anaplastic gliomas over the past 20 years, it would be fair to say that there have been more than a few disappointments and that the real impact of many of these therapies on patients' duration and quality of survival has been minor at best. It is also fair to state that there has been progress in developing new types of chemotherapy and other agents, in devising new treatment strategies, and in gaining a deeper understanding of the problems that must be overcome to treat patients with anaplastic gliomas successfully. The past several years have seen the realization that oligodendroglioma, primary CNS lymphoma, and medulloblastoma are sensitive to chemotherapy treatments. It is hoped that future studies will delineate better the optimal use of chemotherapy for these tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11770297     DOI: 10.1016/s0889-8588(05)70266-5

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  6 in total

1.  Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.

Authors:  Michael A Badruddoja; Kara Penne; Annick Desjardins; David A Reardon; Jeremy N Rich; Jennifer A Quinn; Sith Sathornsumetee; Allan H Friedman; Darell D Bigner; James E Herndon; Ann Cahill; Henry S Friedman; James J Vredenburgh
Journal:  Neuro Oncol       Date:  2006-11-15       Impact factor: 12.300

2.  A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.

Authors:  P Tang; G Roldan; P M A Brasher; D Fulton; W Roa; A Murtha; J G Cairncross; P A Forsyth
Journal:  J Neurooncol       Date:  2006-05-19       Impact factor: 4.130

3.  Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium.

Authors:  Ramsis K Benjamin; Fred H Hochberg; Elizabeth Fox; Peter M Bungay; William F Elmquist; Clinton F Stewart; James M Gallo; Jerry M Collins; Robert P Pelletier; John F de Groot; Robert C Hickner; Idil Cavus; Stuart A Grossman; O Michael Colvin
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

4.  Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.

Authors:  Stephen T Keir; Christopher L Morton; Catherine Billups; Malcolm A Smith; Peter J Houghton; Sridharan Gururangan
Journal:  Pediatr Blood Cancer       Date:  2008-09       Impact factor: 3.167

Review 5.  The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.

Authors:  Peter E Fecci; Duane A Mitchell; Gary E Archer; Michael A Morse; H Kim Lyerly; Darell D Bigner; John H Sampson
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

Review 6.  Current concepts in stereotactic radiosurgery - a neurosurgical and radiooncological point of view.

Authors:  Jan Vesper; B Bölke; C Wille; P A Gerber; C Matuschek; M Peiper; H J Steiger; W Budach; G Lammering
Journal:  Eur J Med Res       Date:  2009-03-17       Impact factor: 2.175

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.